DETERMINATION OF DRUG SUSCEPTIBILITY OF SLOWLY GROWING М. KANSASII
Abstract
We investigated 112 cultures of М. kansasii, by broth microdilution method in SlowMyco (TREK Diagnostic Systems Ltd., GB) test.
We characterized the spectrum of MIC of 13 drugs, detected the number of susceptible, resistant, and intermediate strains to each drug. We established that М. kansasii strains were more often susceptible to amikacin, isoniazid, clarithromycin, linezolid, moxifloxacin and resistant to doxycycline, trimethoprim/ sulfamethoxazole and ciprofloxacin.
We also determined «reserves» of susceptibility («intermediate» susceptibility/resistance) that makes it possible to use drugs in the chemotherapy of mycobacteriosis caused by these NTM more justifiably.
About the Authors
E. N. Khachturiants
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department
Russian Federation
Russian Federation
M. V. Makarova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department
Russian Federation
Russian Federation
M. A. Krasnova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department
Russian Federation
Russian Federation
K. Yu. Galkina
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department
Russian Federation
Russian Federation
A. O. Chizova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department
Russian Federation
Russian Federation
V. I. Litvinov
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department
Russian Federation
Russian Federation
References
1. Литвинов В.И., Богородская Е.М., Борисов С.Е. Нетуберкулезные микобактерии, микобактериозы. – М.: МНПЦБТ, 2014. – 254 с.
2. Оттен Т.Ф., Васильев А.В. Микобактериоз. – СПб.: Мед. пресса, 2005. – 224 с.
3. Adle-Biassette H., Huerre M., Breton G. et al. Non tuberculous mycobacterial diseases // Ann. Pathol. – 2003. – Vol. 23. – N. 3. – P. 216-235.
4. Alcaide F., Calatayud L., Santín M., Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii // Antimicrob. Agents. Chemother. – 2004. – Vol. 48. – N. 12. – P. 4562-4565.
5. Babady N., Hall L., Abbenyi A. et al. Evaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and Just-One strips // J. Clin. Microbiol. – 2010. – Vol. 48. – N. 5. – P. 1749-1752.
6. Brown-Elliott B., Griffith D., Wallace R. Diagnosis of nontuberculous mycobacterial infections // J. Clin. Lab. Med. – 2002. – Vol. 22. – P. 911-925.
7. Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – P. 545-582.
8. CLSI. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard: 2nd Ed. CLSI document M24-A2. – Wayne, PA: Clinical and Laboratory Standards Institute, 2011. [Электронный ресурс]. URL: https://www.clsi.org/media/1463/m24a2_sample.pdf.
9. Daley C. Mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – P. 103-109.
10. da Silva Telles M., Chimara E., Ferrazoli L., Riley L. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates // J. Med. Microbiol. – 2005. – Vol. 54. – Pt. 10. – P. 975-979.
11. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria // Chest. – 2008. – Vol. 133. – N. 1. – P. 243-251.
12. Griffith D., Aksamit T., Brown-Elliott B. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases // Am. J. Respir. Crit. Care Med. – 2007. – Vol. 175. – N. 4. – P. 367-416.
13. Guna R., Muñoz C., Domínguez V. et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii // J. Antimicrob. Chemother. – 2005. – Vol. 55. – N. 6. – P. 950-953.
14. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections. – CRC Press. Boca Raton Ann Arbor Boston. London, 2000. – 212 p.
15. Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria // Semin. Respir. Crit. Care Med. – 2004. – Vol. 25. – N. 3. – P. 283-295.
16. Heidarieh P., Mirsaeidi M., Hashemzadeh M. In Vitro Antimicrobial susceptibility of nontuberculous mycobacteria in Iran // Microb. Drug. Resist. – 2016. – Vol. 22. – N. 2. – P. 172-178. doi:10.1089/mdr.2015.0134.
17. Hoefsloot W., van Ingen J., Andrejak C. et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study // Eur. Respir. J. – 2013. – Vol. 42. – N. 6. – P. 1604-1613.
18. Hombach M., Somoskövi A., Hömke R. et al. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST // Int. J. Med. Microbiol. – 2013. – Vol. 303. – N. 5. – P. 270-276.
19. Johnston J., Chiang L., Elwood K. Mycobacterium kansasii // Microbiol. Spectr. – 2017. – Vol. 5. – N. 1. doi: 10.1128/microbiolspec.TNMI7-0011-2016.
20. Katoch V. Infections due to non-tuberculous mycobacteria (NTM) // Indian. J. Med. Res. – 2004. – Vol. 120. – P. 290-304.
21. Mogami R., Goldenberg T., de Marca P. et al. Pulmonary infection caused by Mycobacterium kansasii: findings on computed tomography of the chest // Radiol. Bras. – 2016. – Vol. 49. – N. 4. – P. 209-213.
22. Moon S., Park H., Jeon K. et al. Clinical significance of Mycobacterium kansasii isolates from respiratory specimens // PLoS One. – 2015. – Vol. 10. – N. 10: e0139621.
23. Prevots D., Marras T. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review // Clin. Chest. Med. – 2015. – Vol. 36. – N. 1. – P. 13-34.
24. Shitrit D., Baum G., Priess R. et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome // Chest. – 2006. – Vol. 129. – N. 3. – P. 771-776.
25. Stout J., Koh W., Yew W. Update on pulmonary disease due to non-tuberculous mycobacteria // Int. J. Infect. Dis. – 2016. – Vol. 45. – P. 123-34.
26. Tao Y., Ninomiya K., Miyazaki M., Aizawa H. Clinical investigation of pulmonary Mycobacterium kansasii infection in our hospital // Kekkaku. – 2002. – Vol. 77. – N. 1. – P. 23-27.
27. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections // Clin. Microbiol. Infect. – 2009. – Vol. 15. – N. 10. – P. 906-910.
28. van Ingen J., Hoefsloot W., de Lange W. et al. Nontuberculous mycobacteria: clinically relevance // Ned. Tijdschr. Geneeskd. – 2010(а). – 154: A1178.
29. van Ingen J., van der Laan T., Dekhuijzen R. et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands // Int. J. Antimicrob. Agents. – 2010(b). – Vol. 35. – N. 2. – P. 169-173.
30. van Ingen J., Kuijper E. Drug susceptibility testing of nontuberculous mycobacteria // Future Microbiol. – 2014. – Vol. 9. – N. 9. – P. 1095-110.
31. Woods G. Susceptibility testing for mycobacteria // Clin. Infect. Dis. – 2000. – Vol. 31. – N. 5. – P. 1209-1215.
32. Wu T., Leu H., Chiu C. et al. Clinical manifestations, antibiotic susceptibility and molecular analysis of Mycobacterium kansasii isolates from a university hospital in Taiwan // J. Antimicrob. Chemother. – 2009. – Vol. 64. – N. 3. – P. 511-514.
Review
For citations:
Khachturiants E.N., Makarova M.V., Krasnova M.A., Galkina K.Yu., Chizova A.O., Litvinov V.I. DETERMINATION OF DRUG SUSCEPTIBILITY OF SLOWLY GROWING М. KANSASII. Tuberculosis and socially significant diseases. 2018;(2):16-21. (In Russ.)
Views:
18
Email this article 